cat no | io1033, io1034
ioMicroglia APOE 4/3 are opti-ox deterministically programmed microglia carrying a genetically engineered heterozygous C112R mutation in the APOE gene, converting the wild-type APOE3 allele to APOE4, encoding the apolipoprotein E4. The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
These cells offer a functional, rapidly maturing, and disease relevant system to study the role of APOE4 in late-onset AD, alongside a genetically matched wild-type control.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Making True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioMicroglia to directly investigate the effect of APOE4 on late-onset AD.
Quick
Rapidly maturing cells that are ready to use within 10 days post-revival, in mono- and co-cultures.
Functional
Disease model cells display key phagocytic and cytokine secretion functions.
Disease model cells express key microglia markers comparably to the genetically matched wild-type control
Disease model cells show expected ramified morphology by day 10
Disease model cells display reduced secretion of pro-inflammatory cytokines, IL-12p70, IL-1β, and TNF⍺, upon activation compared to the genetically matched wild-type control
Elise Malavasi, PhD
Principal Scientist
Concept Life Sciences
bit.bio | Medicines Discovery Catapult
2024
In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.